Treatment Outcome of Hepatic Re-irradiation in Patients With HCC

recurrence-free rates were 80.1%, 57.6% and 31.3%, respectively. The overall survival rates were 100%, 93.4% and 81.5%, respectively. Grade 3 laboratory toxicities were observed in 18 patients and ascites occurred in one patient. Conclusions: Local control and overall survival after SABR for us-HCC were excellent despite the candidates being unfit for resection and ablation therapy. SABR is safe and might be an alternative to resection and ablation therapy. Further prospective studies are warranted to validate the effect of SABR for HCC. Author Disclosure: A. Takeda: None.